The independent Cancer Taskforce’s new five-year strategy for cancer recommends improvements across the pathway, with the aim of improving survival rates, including for patients with advanced melanoma. NHS England is currently working with partners across the health system to determine how best to take forward the recommendations in the strategy, and has appointed Cally Palmer as NHS National Cancer Director to lead on managing its implementation.
In addition, NICE is currently developing a quality standard which will cover prevention, assessment, diagnosis and management of skin cancer (non-melanoma and malignant melanoma) in children, young people and adults. The anticipated publication date for this quality standard is August 2016.
NICE has also recommended a number of drugs for the treatment of melanoma, including: ipilimumab, vemurafenib and pembrolizumab, and is currently in the process of appraising others. More information is available on NICE’s website at: